131 related articles for article (PubMed ID: 1340065)
21. Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR.
Toumpanakis C; Garland J; Marelli L; Srirajaskanthan R; Soh J; Davies P; Buscombe J; Caplin ME
Aliment Pharmacol Ther; 2009 Oct; 30(7):733-40. PubMed ID: 19573169
[TBL] [Abstract][Full Text] [Related]
22. [Results of treatment in patients with hairy cell leukemia with splenectomy, alpha-interferon and deoxycoformycin].
Gotić M; Rolović Z; Radosević N; Draguljac N; Jovanović V; Bogdanović A; Bosković D
Srp Arh Celok Lek; 2000; 128(7-8):262-70. PubMed ID: 11089434
[TBL] [Abstract][Full Text] [Related]
23. Management of gastroentero-pancreatic neuroendocrine tumors (GEP-NETs).
Desai KK; Khan MS; Toumpanakis C; Caplin ME
Minerva Gastroenterol Dietol; 2009 Dec; 55(4):425-43. PubMed ID: 19942827
[TBL] [Abstract][Full Text] [Related]
24. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
25. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues.
De Jong M; Breeman WA; Bernard HF; Kooij PP; Slooter GD; Van Eijck CH; Kwekkeboom DJ; Valkema R; Mäcke HR; Krenning EP
Q J Nucl Med; 1999 Dec; 43(4):356-66. PubMed ID: 10731786
[TBL] [Abstract][Full Text] [Related]
26. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
[TBL] [Abstract][Full Text] [Related]
27. Hepatic artery chemoinfusion with chemoembolization for neuroendocrine cancer with progressive hepatic metastases despite octreotide therapy.
Christante D; Pommier S; Givi B; Pommier R
Surgery; 2008 Dec; 144(6):885-93; discussion 893-4. PubMed ID: 19040993
[TBL] [Abstract][Full Text] [Related]
28. Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors.
Oberg K
Expert Rev Anticancer Ther; 2009 May; 9(5):557-66. PubMed ID: 19445573
[TBL] [Abstract][Full Text] [Related]
29. Treatment of malignant endocrine pancreatic tumors with human leukocyte interferon.
Eriksson B; Oberg K; Alm G; Karlsson A; Lundqvist G; Magnusson A; Wide L; Wilander E
Cancer Treat Rep; 1987 Jan; 71(1):31-7. PubMed ID: 2878718
[TBL] [Abstract][Full Text] [Related]
30. The role of interferons in the management of carcinoid tumors.
Oberg K; Eriksson B
Acta Oncol; 1991; 30(4):519-22. PubMed ID: 1854509
[TBL] [Abstract][Full Text] [Related]
31. Interferon-alpha versus somatostatin or the combination of both in gastro-enteropancreatic tumours.
Oberg K
Digestion; 1996; 57 Suppl 1():81-3. PubMed ID: 8813477
[TBL] [Abstract][Full Text] [Related]
32. Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a. A study by the Italian Trials in Medical Oncology Group.
Bajetta E; Zilembo N; Di Bartolomeo M; Di Leo A; Pilotti S; Bochicchio AM; Castellani R; Buzzoni R; Celio L; Dogliotti L
Cancer; 1993 Nov; 72(10):3099-105. PubMed ID: 7693327
[TBL] [Abstract][Full Text] [Related]
33. Phase II study of continuous infusion fluorouracil and interferon alfa-2b in the palliation of malignant neuroendocrine tumors.
Andreyev HJ; Scott-Mackie P; Cunningham D; Nicolson V; Norman AR; Badve SS; Iveson A; Nicolson MC
J Clin Oncol; 1995 Jun; 13(6):1486-92. PubMed ID: 7751896
[TBL] [Abstract][Full Text] [Related]
34. [Combined treatment of metastatic endocrine tumors of the gastrointestinal tract with octreotide and interferon-alpha].
Nold R; Frank M; Kajdan U; Trost U; Klose KJ; Arnold R
Z Gastroenterol; 1994 Apr; 32(4):193-7. PubMed ID: 7517086
[TBL] [Abstract][Full Text] [Related]
35. Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity.
Oberg K; Alm G; Magnusson A; Lundqvist G; Theodorsson E; Wide L; Wilander E
J Natl Cancer Inst; 1989 Apr; 81(7):531-5. PubMed ID: 2466128
[TBL] [Abstract][Full Text] [Related]
36. [The interferons: pharmacology, mechanism of action, tolerance and side effects].
Arnaud P
Rev Med Interne; 2002 Nov; 23 Suppl 4():449s-458s. PubMed ID: 12481400
[TBL] [Abstract][Full Text] [Related]
37. Treatment of malignant carcinoid tumors with human leukocyte interferon: long-term results.
Oberg K; Norheim I; Lind E; Alm G; Lundqvist G; Wide L; Jonsdottir B; Magnusson A; Wilander E
Cancer Treat Rep; 1986 Nov; 70(11):1297-304. PubMed ID: 2429764
[TBL] [Abstract][Full Text] [Related]
38. Nonsurgical treatment of advanced malignant neuroendocrine pancreatic tumors and midgut carcinoids.
Skogseid B
World J Surg; 2001 Jun; 25(6):700-3. PubMed ID: 11376401
[TBL] [Abstract][Full Text] [Related]
39. An update of the medical treatment of malignant endocrine pancreatic tumors.
Eriksson B; Oberg K
Acta Oncol; 1993; 32(2):203-8. PubMed ID: 8391832
[TBL] [Abstract][Full Text] [Related]
40. The clinical use of interferons in the management of neuroendocrine gastroenteropancreatic tumors.
Oberg K; Eriksson B; Janson ET
Ann N Y Acad Sci; 1994 Sep; 733():471-8. PubMed ID: 7978897
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
